Thorax 63:725-731 doi:10.1136/thx.2007.092056
  • Cystic fibrosis

Outcomes of lung transplantation for cystic fibrosis in a large UK cohort

  1. G Meachery1,
  2. A De Soyza2,
  3. A Nicholson3,
  4. G Parry1,
  5. A Hasan1,
  6. K Tocewicz1,
  7. T Pillay1,
  8. S Clark1,
  9. J L Lordan1,2,
  10. S Schueler1,
  11. A J Fisher1,2,
  12. J H Dark1,
  13. F K Gould3,
  14. P A Corris1,2
  1. 1
    Department of Cardiopulmonary Transplantation, The Freeman Hospital, High Heaton, Newcastle-upon-Tyne, UK
  2. 2
    Applied Immunobiology and Transplantation, Institute of Cellular Medicine, University of Newcastle, UK
  3. 3
    Department of Medical Microbiology, The Freeman Hospital, High Heaton, Newcastle-upon-Tyne, UK
  1. Dr A De Soyza, Applied Immunobiology and Transplantation, Institute of Cellular Medicine, University of Newcastle, Newcastle-upon-Tyne NE7 7DN, UK;{at}
  • Received 31 October 2007
  • Accepted 26 March 2008
  • Published Online First 16 May 2008


Background: Lung transplantation is an important option to treat patients with advanced cystic fibrosis (CF) lung disease. The outcomes of a large UK cohort of CF lung transplantation recipients is reported.

Methods: Retrospective review of case notes and transplantation databases.

Results: 176 patients with CF underwent lung transplantation at our centre. The majority (168) had bilateral sequential lung transplantation. Median age at transplantation was 26 years. Diabetes was common pretransplantation (40%). Polymicrobial infection was common in individual recipients. A diverse range of pathogens were encountered, including the Burkholderia cepacia complex (BCC). The bronchial anastomotic complication rate was 2%. Pulmonary function (forced expiratory volume in 1 s % predicted) improved from a pretransplantation median of 0.8 l (21% predicted) to 2.95 l (78% predicted) at 1 year following transplantation. We noted an acute rejection rate of 41% within the first month. Our survival values were 82% survival at 1 year, 70% at 3 years, 62% at 5 years and 51% at 10 years. Patients with BCC infection had poorer outcomes and represented the majority of those who had a septic death. Data are presented on those free from these infections. Bronchiolitis obliterans syndrome (BOS) and sepsis were common causes of death. Freedom from BOS was 74% at 5 years and 38% at 10 years. Biochemical evidence of renal dysfunction was common although renal replacement was infrequently required (<5%).

Conclusion: Lung transplantation is an important therapeutic option in patients with CF even in those with more complex microbiology. Good functional outcomes are noted although transplantation associated morbidities accrue with time.


  • See Editorial, page 668, and page 732

  • Funding: ADS was supported by a HEFCE Senior Lectuereship.

  • Competing interests: None.